KALLISIO INC.

Kallisio develops patient-specific solutions to support precision radiation therapy. The company’s flagship Stentra™ system delivers a custom oral immobilization and tongue displacement device in as little as 72 hours. Easily integrated into existing oncology workflows, Stentra drives improved dose targeting accuracy and healthy tissue protection for head and neck cancer patients. Stentra uses patient imaging and advanced 3D printing to create individualized intraoral devices that position and stabilize the tongue, lips, and other organs at risk during radiation therapy. By reducing anatomical variability, Stentra supports sub-millimeter dose precision and helps protect healthy tissue from unnecessary exposure. FDA cleared, CE marked and deployed at leading cancer centers, Stentra delivers clear clinical and commercial value by improving radiotherapy accuracy as well as reducing rework and toxicity-related interruptions. Ask about our risk-free proof of value pilot program with full onboarding and support.